962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing

BACKGROUND: Liposomal amphotericin B (L-amB, AmBisome®) is popular for off-label use in the treatment of cutaneous leishmaniasis (CL) using dosing of 3 mg/kg/day for days 1–5, 8, 9, or days 1–5, 10 with reported clinical cure rates of 46–84%. In rodents, the skin concentration of L-amB is 40-fold le...

Descripción completa

Detalles Bibliográficos
Autores principales: Aronson, Naomi E, Koles, Nancy, Moran, Sean, Zhang, Aihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253134/
http://dx.doi.org/10.1093/ofid/ofy209.078

Ejemplares similares

Ejemplares similares